title: Quantitative chemiluminescent immunoassay of p53: prognostic significance in 220 node-negative breast cancer tissue.
abstract: The prognostic and predictive role of p53 overexpression in breast cancer samples is usually investigated by using molecular biology or immunohistochemical methods. However, the results are to date controversial, and this is in part due to the methodological pitfalls of both the methods. To study the possibility of overcoming, at least in part, these problems we evaluated a commercially available chemiluminescent immunoassay with which the p53 concentrations of 220 specimens from node negative breast cancer were determined. The assay showed good analytical performance and found detectable levels in 84.7% of cases (median 0.22 ng/mg of proteins, range 0-50 ng/mg of proteins). p53 has been found inversely correlated with estrogen receptors and directly correlated with cathepsin D. The prognostic role of p53 was evaluated in two different ways: a) two previous studies (Borg et al 1995, DeWitte et al. 1996) using the same method found almost 30% of samples had significantly shorter DFS and OS. We subdivided our cases in order to identify the same positivity rate and to verify if the previous cathegorizations were effective also in our patient series. We confirmed the independent association with DFS (p = 0.006) and OS (p = 0.0005); b) considering that any categorization of quantitative parameters could cause a loss of clinical information, we also evaluated p53 as a continuous variable. Multivariate analysis showed a significant quantitative relationship between p53 and both disease free (p = 0.026) and overall survival (p = 0.02).
authors.affiliation: Center for the Study of Biological Markers of Malignancy, P.F. Calvi Hospital, Noale, Italy.
authors.forename: R
authors.initials: R
authors.lastname: Dittadi
authors.forename: A
authors.initials: A
authors.lastname: Brazzale
authors.forename: R
authors.initials: R
authors.lastname: Mione
authors.forename: S
authors.initials: S
authors.lastname: Di Fresco
authors.forename: C
authors.initials: C
authors.lastname: Gatti
authors.forename: O
authors.initials: O
authors.lastname: Vinante
authors.forename: F
authors.initials: F
authors.lastname: Bassan
authors.forename: O
authors.initials: O
authors.lastname: Nascimben
authors.forename: M
authors.initials: M
authors.lastname: Gion
mesh_terms: D000368:Aged; D001943:Breast Neoplasms / Q000401:mortality / Q000473:pathology*; D002402:Cathepsin D / Q000032:analysis; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007118:Immunoassay / Q000379:methods; D008163:Luminescent Measurements; D008198:Lymph Nodes / Q000473:pathology; D008875:Middle Aged; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D011379:Prognosis; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis; D015203:Reproducibility of Results; D015996:Survival Rate; D016159:Tumor Suppressor Protein p53 / Q000032:analysis*
chemical_list: D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D016159:Tumor Suppressor Protein p53; D002402:Cathepsin D